The drug, Talicia, is an oral capsule comprising two antibiotics,
amoxicillin and rifabutin, as well as omeprazole, a common treatment
The Israel-based company said the drug was designed to address the
high resistance of H. pylori bacteria to current clarithromycin-based
RedHill expects to launch Talicia in the United States in the first
quarter next year.
[to top of second column]
Helicobacter pylori infection affects over 50% of the population
worldwide, according to Redhill, and is one of the strongest risk
factors in the development of gastric cancer.
(Reporting by Manas Mishra in Bengaluru; Editing by Anil D'Silva and
[© 2019 Thomson Reuters. All rights
Copyright 2019 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content.